Systemic Effects After Local Injection of Platelet-rich Plasma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Platelet Rich Plasma (PRP)
- Sponsor
- Chang Gung Memorial Hospital
- Enrollment
- 24
- Locations
- 1
- Primary Endpoint
- Urinary excretion of endogenous AAS metabolites
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
Objective Platelet-rich plasma (PRP) is widely utilized in the treatment of sports injuries with favorable outcomes. However, potential systemic effects after localized PRP injection are unclear at present.
Design: prospective randomized study Methods Twenty-four Taiwanese male athletes with tendinopathy were randomized into a PRP group (n = 13) or a saline group (n = 11).
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Receive local injections and surgery within three months
- •Systemic disease
- •Diagnosis of anemia
Outcomes
Primary Outcomes
Urinary excretion of endogenous AAS metabolites
Time Frame: 1 week
Doping substances in urine, mainly metabolites of anabolic androgenic steroids (AAS), were quantified, including testosterone (17β-hydroxyandrost-4-en-3-one), epitestosterone (17α- hydroxy-4-androsten-3-one), androsterone (4-androsten-3,17-dione), etiocholanolone (3α-hydroxy-5β-androstan-17-one), DHEA (dehydroepiandrosterone), dihydroandrosterone (5α- androstane-3α,17β-diol), and etiocholane-3α,17β-diol (5β -androstane-3α,17β-diol). Each urine sample (6 mL) was mixed with 50 μL standard solution and 1 mL phosphate buffer, and the mixture was heated for 60 min at 50°C. After cooling at room temperature, liquid-liquid extraction was performed, and phase separation was achieved. The organic extract was evaporated to dryness, and the dried residue was further derivatized with 50 μL of MSTFA solution for 30 min at 60°C. Finally, the sample was subjected to gas chromatographic analysis and mass spectrometric analysis for quantification of doping substances of interest.